Ipsen’s Palovarotene Ultra-Rare Bone Disorder Drug Faces Hurdles At US FDA Adcomm

Boat uncertainty
Fate of Ipsen's rare disease drug palovarotene is uncertain given questions raised about study data • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers